NewAmsterdam Pharma

NewAmsterdam Pharma is a biopharmaceutical company focused on advancing treatments for cardiovascular disease and other lipid-related conditions. The company is investigating a novel mechanism of action, cholesteryl ester transfer protein (CETP) inhibition, to help patients reach their LDL-C goals. It was co-founded by Professor Dr. John Kastelein and venture capital firm Forbion. The company acquired rights for obicetrapib from a subsidiary of Amgen in January 2020 and is developing it as a potential therapy. NewAmsterdam Pharma is publicly traded on the Nasdaq under the ticker NAMS.

NewAmsterdam Pharma was co-founded by Professor Dr. John Kastelein and venture capital firm Forbion. In January 2020, the company acquired all rights for obicetrapib, a novel, selective cholesteryl ester transfer protein (CETP) inhibitor, from a subsidiary of Amgen. In April 2020, Dr. Michael Davidson joined as co-founding Chief Executive Officer. In August 2020, the company completed a $196M (€160M) Series A funding round. In November 2021, it dosed first patients in Phase 3 BROADWAY and PREVAIL trials. In January-April 2022, it signed a licensing deal with the Menarini Group. In June 2022, it dosed first patient in Phase 3 BROOKLYN trial. In July 2022, it debuted on the Nasdaq as a publicly traded company (Nasdaq: NAMS) and raised $328 million in gross proceeds. In November 2022, it presented full data from Phase 2 ROSE2 trial. In June 2023, it began evolution into a commercial organization with appointment of first Chief Commercial Officer, B.J. Jones. In August 2023, it generated net proceeds of $190 million via an upsized public offering.

1. 1NewAmsterdam Pharma: Science-Backed and Patient-Focusednewamsterdampharma.com
2. 2NewAmsterdam Pharma: Our Mission, History, and Culturenewamsterdampharma.com
3. 3NewAmsterdam Pharma (Netherlands)wikidata.org
4. 4NewAmsterdam Pharma Acquires Obicetrapib from Amgenfinanznachrichten.de